Biomolecular Factors Represented by Bcl-2, p53, and Tumor-Infiltrating Lymphocytes Predict Response for Adjuvant Anthracycline Chemotherapy in Patients with Early Triple-Negative Breast Cancer

References

• Dawood S. Triple-negative breast cancer: epidemiology and management options. Drugs. 2010;70(17):2247–2258. doi:10.2165/11538150-000000000-0000021080741
   PubMed Web of Science ®Google Scholar
• Gamucci T, Vaccaro A, Ciancola F, et al. Recurrence risk in small, node negative, early breast cancer: a multicenter retrospective analysis. J Cancer Res Clin Oncol. 2013;139(5):853–860. doi:10.1007/s00432-013-1388-223411686
   PubMed Web of Science ®Google Scholar
• Heys SD, Hutcheon AW, Sarkar TK, et al. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer. 2002;3(Suppl 2):S69–S74. doi:10.3816/CBC.2002.s.01512435290
   PubMedGoogle Scholar
• Azim HA Jr, de Azambuja E, Colozza M, Bines J, Piccart MJ. Long-term toxic effects of adjuvant chemotherapy in breast cancer. Ann Oncol. 2011;22(9):1939–1947. doi:10.1093/annonc/mdq68321289366
   PubMed Web of Science ®Google Scholar
• Ghigo A, Li M, Hirsch E. New signal transduction paradigms in anthracycline-induced cardiotoxicity. Biochim Biophys Acta. 2016;pii: S0167–4889(16)30011–8.
   PubMed Web of Science ®Google Scholar
• Praga C, Bergh J, Bliss J, et al. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol. 2005;23:4179–4191. doi:10.1200/JCO.2005.05.02915961765
   PubMed Web of Science ®Google Scholar
• Tanner M, Isola J, Wiklund T, et al. Topoisomerase II alpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol. 2006;24(16):2428–2436. doi:10.1200/JCO.2005.02.926416682728
   PubMed Web of Science ®Google Scholar
• Sinn HP, Schneeweiss A, Keller M, et al. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer. BMC Cancer. 2017;17(1):124. doi:10.1186/s12885-017-3111-128193205
   PubMedGoogle Scholar
• Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010;134(6):907–922.20524868
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists Guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118–145. doi:10.1200/JCO.2006.09.277517159189
   PubMed Web of Science ®Google Scholar
• Hamzehloie T, Mojarrad M, Hasanzadeh Nazarabadi M, Shekouhi S. The role of tumor protein 53 mutations in common human cancers and targeting the murine double minute 2-p53 interaction for cancer therapy. Iran J Med Sci. 2012;37(1):3–8.23115424
   PubMedGoogle Scholar
• Tsuda H, Hirohashi S. Association among p53 gene mutation, nuclear accumulation of the p53 protein and aggressive phenotypes in breast cancer. Int J Cancer. 1994;57(4):498–503. doi:10.1002/ijc.29105704107910151
   PubMed Web of Science ®Google Scholar
• Ilie SM, Bacinschi XE, Botnariuc I, Anghel RM. Potential clinically useful prognostic biomarkers in triple-negative breast cancer: preliminary results of a retrospective analysis. Breast Cancer. 2018;10:177–194.30538542
   PubMed Web of Science ®Google Scholar
• Chae BJ, Bae JS, Lee A, et al. p53 as a specific prognostic factor in triple-negative breast cancer. Jpn J Clin Oncol. 2009;39(4):217–224. doi:10.1093/jjco/hyp00719304743
   PubMed Web of Science ®Google Scholar
• Bae SY, Nam SJ, Jung Y, et al. Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer. Breast Cancer Res Treat. 2018;172(2):437–444. doi:10.1007/s10549-018-4928-230132220
   PubMed Web of Science ®Google Scholar
• Lee M, Park IA, Heo SH, Kim YA, Gong G, Lee HJ. Association between p53 expression and amount of tumor-infiltrating lymphocytes in triple-negative breast cancer. J Pathol Transl Med. 2019;53(3):180–187. doi:10.4132/jptm.2019.02.0830853706
   PubMed Web of Science ®Google Scholar
• Xu YL, Yao R, Li J, et al. FOXC1 overexpression is a marker of poor response to anthracycline-based adjuvant chemotherapy in sporadic triple-negative breast cancer. Cancer Chemother Pharmacol. 2017;79(6):1205–1213. doi:10.1007/s00280-017-3319-428493031
   PubMed Web of Science ®Google Scholar
• Gaulard P, d’Agay MF, Peuchmaur M, et al. Expression of the Bcl-2 gene product in follicular lymphoma. Am J Pathol. 1992;140(5):1089–1095.1374590
   PubMed Web of Science ®Google Scholar
• Zubair M, Hashmi SN, Afzal S, et al. Immunohistochemical expression of B cell lymphoma2 with clinicopathological correlation in triple negative breast cancers in northern Pakistan. Asian Pac J Cancer Prev. 2016;17(7):3619–3622.27510019
   PubMedGoogle Scholar
• Dawson SJ, Makretsov N, Blows FM, et al. BCL2 in breast cancer a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received [published correction appears in Br J Cancer. 2010 Sep 28;103(7):1137]. Br J Cancer. 2010;103(5):668–675.20664598
   PubMed Web of Science ®Google Scholar
• Ohmori T, Podack ER, Nishio K, et al. Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by Bcl-2. Biochem Biophys Res Commun. 1993;192(1):30–36. doi:10.1006/bbrc.1993.13778476431
   PubMed Web of Science ®Google Scholar
• Abdel-Fatah TM, Perry C, Dickinson P, et al. Bcl-2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings. Ann Oncol. 2013;24(11):2801–2807. doi:10.1093/annonc/mdt27723908177
   PubMed Web of Science ®Google Scholar
• Choi JE, Kang SH, Lee SJ, Bae YK. Prognostic significance of Bcl-2 expression in non-basal triple-negative breast cancer patients treated with anthracycline-based chemotherapy. Tumour Biol. 2014;35(12):12255–12263. doi:10.1007/s13277-014-2534-425179840
   PubMedGoogle Scholar
• Bouchalova K, Svoboda M, Kharaishvili G, et al. BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy. Tumour Biol. 2015;36(6):4243–4252. doi:10.1007/s13277-015-3061-725616695
   PubMedGoogle Scholar
• Burugu S, Asleh-Aburaya K, Nielsen TO. Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication. Breast Cancer. 2016;2.
   Google Scholar
• Casares N, Pequignot MO, Tesniere A, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med. 2005;202(12):1691–1701. doi:10.1084/jem.2005091516365148
   PubMed Web of Science ®Google Scholar
• Ali HR, Provenzano E, Dawson SJ, et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann Oncol. 2014;25(8):1536–1543. doi:10.1093/annonc/mdu19124915873
   PubMed Web of Science ®Google Scholar
• Ibrahim EM, Al-Foheidi ME, Al-Mansour MM, Kazkaz GA. The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis. Breast Cancer Res Treat. 2014;148(3):467–476.25361613
   PubMed Web of Science ®Google Scholar
• Adams S, Gray RJ, Demaria S, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32:2959–2966. doi:10.1200/JCO.2013.55.049125071121
   PubMed Web of Science ®Google Scholar
• Ladoire S, Mignot G, Dalban C, et al. FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial. Ann Oncol. 2012;23(10):2552–2561. doi:10.1093/annonc/mds02822431701
   PubMed Web of Science ®Google Scholar
• West NR, Milne K, Truong PT, Macpherson N, Nelson BH, Watson PH. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res. 2011;13(6):R126. doi:10.1186/bcr307222151962
   PubMed Web of Science ®Google Scholar
• Dieci MV, Mathieu MC, Guarneri V, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. Ann Oncol. 2015;26(8):1698–1704. doi:10.1093/annonc/mdv23925995301
   PubMed Web of Science ®Google Scholar
• Pruneri G, Vingiani A, Bagnardi V, et al. Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer. Ann Oncol. 2016;27(2):249–256. doi:10.1093/annonc/mdv57126598540
   PubMed Web of Science ®Google Scholar
• Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31(7):860–867. doi:10.1200/JCO.2011.41.090223341518
   PubMed Web of Science ®Google Scholar
• Wang K, Xu J, Zhang T, Xue D. Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: a meta-analysis. Oncotarget. 2016;7(28):44288–44298. doi:10.18632/oncotarget.998827329588
   PubMedGoogle Scholar
• Carbognin L, Pilotto S, Nortilli R, et al. Predictive and prognostic role of tumor-infiltrating lymphocytes for early breast cancer according to disease subtypes: sensitivity analysis of randomized trials in adjuvant and neoadjuvant setting. Oncologist. 2016;21(3):283–291. doi:10.1634/theoncologist.2015-030726865589
   PubMed Web of Science ®Google Scholar